Side | BCRL | No BCRL | p-value | ||||
---|---|---|---|---|---|---|---|
Left | Right | Total | Left | Right | Total | ||
(n = 21) | (n = 41) | (n = 62) | (n = 140) | (n = 130) | (n = 270) | ||
Age at diagnosis, years, mean ± SD | 60.4 ± 12.5 | 56.6 ± 13.0 | 57.9 ± 12.8 | 58.7 ± 13.0 | 60.4 ± 13.0 | 59.5 ± 13.0 | 0.4734 |
BMI, n (%)a | 0.5432 | ||||||
Underweight | 0 | 1 (2.4) | 1 (1.6) | 4 (2.9) | 1 (0.8) | 5 (1.9) | |
Normal weight | 14 (66.7) | 13 (31.7) | 27 (43.6) | 66 (47.1) | 55 (42.3) | 121 (44.8) | |
Overweight | 3 (14.3) | 18 (43.9) | 21 (33.9) | 26 (18.6) | 44 (33.8) | 70 (25.9) | |
Obesity | 4 (19.0) | 9 (22.0) | 13 (21.0) | 44 (31.4) | 30 (23.1) | 74 (27.4) | |
Menopause, n (%)b | 0.2647 | ||||||
Pre-menopausal | 5 (23.8) | 16 (39.0) | 21 (33.9) | 45 (32.1) | 34 (26.2) | 79 (29.3) | |
Peri-menopausal | 0 | 0 | 0 (0.0) | 5 (3.6) | 5 (3.8) | 10 (3.7) | |
Post-menopausal | 16 (76.2) | 25 (61.0) | 41 (66.1) | 90 (64.3) | 91 (70.0) | 181 (67.0) | |
Axillary surgery, n (%) | 0.0503 | ||||||
Radical lymph node dissection | 21 (100) | 41 (100) | 62 (100) | 130 (92.8) | 123 (94.6) | 253 (93.7) | |
Sentinel lymph node dissection | 0 | 0 | 0 | 10 (7.2) | 7 (5.4) | 17 (6.3) | |
Radiotherapy, n (%) | 0.3536 | ||||||
Breast | 11 (52.4) | 22 (53.6) | 33 (53.2) | 76 (54.3) | 72 (55.4) | 148 (54.8) | |
Breast and supraclavicular fossa | 1 (4.8) | 6 (14.6) | 7 (11.3) | 7 (5.0) | 7 (5.4) | 14 (5.2) | |
Supraclavicular fossa and chest wall | 4 (19.0) | 4 (9.8) | 8 (12.9) | 22 (15.7) | 17 (13.1) | 39 (14.4) | |
No | 5 (23.8) | 9 (22.0) | 14 (22.6) | 35 (25.0) | 34 (26.1) | 69 (25.6) | |
Chemotherapy, n (%) | 0.0025 | ||||||
Taxane-based protocol | 11 (52.4) | 27 (65.9) | 38 (61.3) | 61 (43.6) | 40 (30.8) | 101 (37.4) | |
Other protocols | 1 (4.8) | 4 (9.7) | 5 (8.1) | 14 (10.0) | 14 (10.8) | 28 (10.4) | |
No | 9 (42.9) | 10 (24.4) | 19 (30.7) | 65 (46.4) | 76 (58.4) | 141 (52.2) | |
Hormone therapy, n (%) | 0.0959 | ||||||
Yes | 16 (76.2) | 34 (82.9) | 50 (80.7) | 128 (91.4) | 111 (85.4) | 239 (88.5) | |
No | 5 (23.8) | 7 (17.1) | 12 (19.3) | 12 (8.6) | 19 (14.6) | 31 (11.5) | |
Trastuzumab, n (%) | 0.0140 | ||||||
Yes | 2 (9.5) | 7 (17.1) | 9 (14.5) | 7 (5.0) | 8 (6.2) | 15 (5.6) | |
No | 19 (90.5) | 34 (82.9) | 53 (85.5) | 133 (95.0) | 122 (93.8) | 255 (94.4) |